2381089-83-2
Most orderedRetatrutide
Single-molecule agonist at the GIP, GLP-1 and glucagon receptors. Supplied lyophilised and released at ≥ 99.0% by RP-HPLC.
Typical release99.4%
From
£68.00
In stock
Metabolic & IncretinMost ordered
Tirzepatide
LY3298176
Dual GIP and GLP-1 receptor agonist. The intermediate step between mono- and tri-agonism.
Total, ex VAT
£84.00
- Released at ≥ 99.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Average mass
- 4813.45 g/mol
- Residues
- 39
- Class
- GIP / GLP-1 dual receptor agonist
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 99.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Glucose-dependent insulinotropic polypeptide receptor (GIPR)
- Glucagon-like peptide-1 receptor (GLP-1R)
Overview
About Tirzepatide
Tirzepatide is a 39-residue synthetic peptide built on the GIP backbone with substitutions that add GLP-1 receptor activity, plus a C20 diacid for albumin binding. Its receptor balance is deliberately asymmetric — it is a more potent GIP receptor agonist than it is a GLP-1 receptor agonist — which is itself a variable of interest in the literature.
Because it sits between the mono-agonists and the tri-agonists, tirzepatide is the compound that isolates the GIP contribution. Studies comparing it against a GLP-1-only reference on one side and a tri-agonist on the other are how the field has assigned effects to specific receptor arms.
In short
- Dual agonist with deliberately unbalanced GIPR-over-GLP-1R potency
- C20 fatty diacid conjugation for once-weekly exposure in preclinical models
- Isolates the GIP receptor contribution in multi-agonist comparisons
- Released at ≥ 99.0% area-percent by RP-HPLC
Where it is used
Research applications
Receptor arm attribution
Positioned between mono- and tri-agonists in comparison studies, letting the GIP contribution be assigned separately from GLP-1 and glucagon effects.
Biased agonism
Reported to produce biased signalling at GLP-1R with reduced β-arrestin recruitment, a mechanism studied for its effect on receptor internalisation.
Adipose tissue biology
GIP receptor expression in adipose tissue makes the compound relevant to work on lipid storage and adipocyte function.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of Tirzepatide and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Dual agonist characterisation
Preclinical and early clinical work describing the receptor pharmacology and the imbalanced potency profile relative to native ligands.
Coskun et al., Molecular Metabolism, 2018
Phase 3 weight management
A large trial reporting substantial weight reduction, which established dual agonism as clinically distinct from GLP-1 mono-agonism.
Jastreboff et al., New England Journal of Medicine, 2022
Questions
Tirzepatide — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- How does this differ from retatrutide?
- Tirzepatide engages two receptors, GIPR and GLP-1R. Retatrutide adds glucagon receptor agonism as a third arm. Comparing them is the standard way of isolating what the glucagon contribution does.
- What purity is it released at?
- ≥ 99.0% area-percent by RP-HPLC, with identity confirmed by ESI-MS against a theoretical average mass of 4813.45 g/mol.
- Is it stable in solution?
- Yes, for 28 days at 2–8 °C. As with all lipidated peptides, avoid mechanical agitation, which promotes aggregation.
Same class
Others in Metabolic & Incretin
910463-68-2
Most orderedSemaglutide
Acylated GLP-1 receptor agonist with a C18 diacid linker. The reference mono-agonist for incretin work.
Typical release99.4%From
£44.00
In stock
Research compound
5-Amino-1MQ
Small-molecule NNMT inhibitor used in methylation and adipocyte metabolism research.
Typical release98.6%From
£56.00
In stock
221231-10-3
AOD-9604
Modified C-terminal growth hormone fragment with a tyrosine addition, studied in lipolysis models.
Typical release98.9%From
£49.00
In stock
Important
Tirzepatide is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.